Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<